Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer.

Colitis colorectal cancer piperlongumine

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2020
Historique:
received: 24 07 2020
accepted: 06 10 2020
entrez: 21 12 2020
pubmed: 22 12 2020
medline: 22 12 2020
Statut: epublish

Résumé

Colorectal cancer is one of the most common and lethal cancers in the world. An important causative factor of colorectal cancer is ulcerative colitis. In this study, we investigated the therapeutic effects of piperlongumine (PL) on the dextran sulfate sodium (DSS)-induced acute colitis and azoxymethane (AOM)/DSS-induced colorectal cancer mouse models. Our results showed that PL could inhibit the inflammation of DSS-induced mouse colitis and reduce the number of large neoplasms (diameter >2 mm) of AOM/DSS-induced mouse colorectal cancer by downregulation of proinflammatory cytokines cyclooxygenase-2 and interleukin-6 and epithelial-mesenchymal transition-related factors, β-catenin, and snail expressions, but fail to improve the colitis symptoms and to decrease the incidence of colonic neoplasms and the number of small neoplasms (diameter <2 mm). These data suggested that PL might be an effective agent in treating colitis and colorectal cancer.

Identifiants

DOI: 10.3389/fphar.2020.586885 PMID: 33343354 PMC: PMC7748110
pubmed: 33343354
doi: 10.3389/fphar.2020.586885
pii: 586885
pmc: PMC7748110
doi:

Types de publication

Journal Article

Langues

eng

Pagination

586885

Informations de copyright

Copyright © 2020 Huang, Wang, Wei, Liu, Fu, Xing and Shi.

Références

Clin Cancer Res. 2016 Aug 15;22(16):4158-69
pubmed: 27528734
Onco Targets Ther. 2020 Jun 15;13:5591-5603
pubmed: 32606774
Cancer Lett. 2017 Feb 1;386:100-109
pubmed: 27864115
Anticancer Res. 2018 Nov;38(11):6231-6236
pubmed: 30396942
Dig Dis. 2012;30 Suppl 1:91-4
pubmed: 23075875
Eur J Pharm Sci. 2013 Feb 14;48(3):453-63
pubmed: 23238172
Oncol Lett. 2015 Aug;10(2):709-715
pubmed: 26622558
Nat Rev Immunol. 2015 Oct;15(10):615-29
pubmed: 26358393
Cancer Lett. 2014 Apr 10;345(2):235-41
pubmed: 23941831
Front Pharmacol. 2018 Sep 28;9:1041
pubmed: 30323762
Cancer Lett. 2019 May 28;450:42-52
pubmed: 30790679
Cells. 2020 Mar 04;9(3):
pubmed: 32143413
Biomed Pharmacother. 2019 Jan;109:1462-1477
pubmed: 30551398
Pathol Res Pract. 2015 Aug;211(8):557-69
pubmed: 26092594
Front Oncol. 2019 Nov 29;9:1345
pubmed: 31850227
Methods Mol Biol. 2016;1438:245-54
pubmed: 27150094
Oxid Med Cell Longev. 2014;2014:906804
pubmed: 24895529
J Surg Oncol. 2010 Jun 15;101(8):706-12
pubmed: 20512947
Pharmacol Res. 2020 Jun;156:104772
pubmed: 32283222
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Cell Death Dis. 2019 Aug 8;10(8):600
pubmed: 31395855
Biochem Biophys Res Commun. 2013 Jul 19;437(1):87-93
pubmed: 23796709

Auteurs

Jia-Rong Huang (JR)

Department of Cell Biology, Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, China.

Sheng-Te Wang (ST)

Department of Cell Biology, Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, China.

Meng-Ning Wei (MN)

Department of Cell Biology, Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, China.

Kun Liu (K)

Department of Cell Biology, Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, China.

Jing-Wen Fu (JW)

Affiliated High School of South China Normal University, Guangzhou, China.

Zi-Hao Xing (ZH)

Department of Cell Biology, Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, China.

Zhi Shi (Z)

Department of Cell Biology, Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, China.

Classifications MeSH